Clinical Characteristics of Importance to Outcome in Patients With Spondyloarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-01

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to investigate extra-articular manifestations, pain mechanisms, patient-reported outcomes, comorbidities and association between these conditions in patients with spondyloarthropathy (SpA) treated with Biologics. Further, to assess the predictive value of baseline pain profile on treatment outcome after ≥ 3 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Early-stage Spondyloarthritis

NCT04095169

Ankylosing Spondylitis Spondyloarthritis

COMPLETED

Impact of Environmental Factors on Disease Activity in Spondyloarthritis (SPA): Results of the Prospective Co-Env Cohort

NCT01314547

Spondylarthritis Primary Systemic Vasculitis

COMPLETED

Factors for the Onset and Course of Axial Spondylitis

NCT06594107

Axial Spondyloarthritis

RECRUITING

Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis

NCT02572700

Psoriatic Arthritis Psoriasis Healthy Controls

UNKNOWN

Diagnostic Criteria in the Diagnosis of Spinal Spondyloarthropathies in Patients With Chronic Low Back Pain (Study P05320)(COMPLETED)

NCT00726765

Spinal Spondyloarthropathies Axial Spondyloarthritis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with spondyloarthropaty, who initiate or switch biologics in routine care due to an active disease state, will be enrolled in this observational study.

The overall aim is to investigate extra-articular manifestations, pain mechanisms and patient-reported outcomes and elucidate if these factors - independently or by interaction - influence treatment response after ≥ 3 months. Patients will have a baseline visit, an eye examination and a follow up visit after ≥ 3 months. Clinical examinations will be performed at both time points and include:

1. Clinical examination (the spinal movement)
2. Assessment of pain mechanisms by clinical evaluation (BASDAI, tender points,) and pain questionnaires (PainDETECT).
3. The SPARCC Enthesitis Index will be used to enthesitis count.
4. Interview and questionnaires regarding lifestyle, comorbidity, function and quality of life
5. Blood samples
6. Urine samples
7. Stool samples

Clinical as well as patient-reported and observer-based outcomes will be described for the overall study population and the prognostic influence of extra-articular manifestations, comorbidity and pain mechanisms will be analysed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondyloarthropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with SpA
* ≥18 years of age at time of consent
* Ability and willingness to give written informed consent and to meet the requirements of this protocol
* Patients must have a history of active disease and a BASDAI \>40 (10-100) or elevated C-reactive protein, despite current or previous NSAIDs therapy

Exclusion Criteria

* Age \< 18 years
* No consent
* Pregnancy
* Active or latent TB
* Diagnosed Human immunodeficiency virus
* Diagnosed hepatitis
* Current or past malignant disease
* Recurrent or chronic infection (viral, fungal or bacterial)
* Multiple sclerosis
* Heart failure (NYHA class III/IV)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No